Crestwood Advisors Group LLC Has $21.91 Million Stake in Stryker Corporation (NYSE:SYK)

Crestwood Advisors Group LLC lowered its stake in Stryker Corporation (NYSE:SYK - Free Report) by 41.5% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 58,866 shares of the medical technology company's stock after selling 41,814 shares during the quarter. Crestwood Advisors Group LLC's holdings in Stryker were worth $21,913,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Capital A Wealth Management LLC purchased a new position in Stryker during the 4th quarter valued at approximately $26,000. Goodman Advisory Group LLC bought a new stake in shares of Stryker in the 1st quarter valued at approximately $32,000. City Holding Co. lifted its stake in shares of Stryker by 528.6% in the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after purchasing an additional 74 shares during the last quarter. Smallwood Wealth Investment Management LLC bought a new stake in shares of Stryker in the 1st quarter valued at approximately $40,000. Finally, Itau Unibanco Holding S.A. bought a new stake in shares of Stryker in the 4th quarter valued at approximately $42,000. Institutional investors own 77.09% of the company's stock.

Stryker Stock Down 0.5%

Shares of NYSE SYK traded down $1.82 on Monday, hitting $387.58. The company had a trading volume of 791,681 shares, compared to its average volume of 1,349,256. Stryker Corporation has a 12-month low of $314.93 and a 12-month high of $406.19. The business has a 50 day moving average of $385.67 and a two-hundred day moving average of $378.19. The company has a quick ratio of 1.00, a current ratio of 1.64 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $147.94 billion, a P/E ratio of 52.38, a PEG ratio of 2.94 and a beta of 0.91.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. Stryker had a return on equity of 23.74% and a net margin of 12.31%. The company had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.68 billion. During the same quarter in the previous year, the firm posted $2.50 EPS. The firm's quarterly revenue was up 11.9% on a year-over-year basis. As a group, equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be paid a dividend of $0.84 per share. The ex-dividend date is Monday, June 30th. This represents a $3.36 annualized dividend and a yield of 0.87%. Stryker's dividend payout ratio is 45.41%.

Wall Street Analysts Forecast Growth

Several research firms have commented on SYK. BTIG Research reiterated a "buy" rating on shares of Stryker in a research note on Monday, July 14th. Citigroup reiterated a "buy" rating and issued a $455.00 price objective (up from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. Evercore ISI raised their price target on Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Roth Mkm raised their price target on Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Finally, Sanford C. Bernstein set a $450.00 target price on Stryker in a research report on Monday, May 5th. Four analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $428.55.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director directly owned 3,417,326 shares of the company's stock, valued at $1,288,195,208.96. The trade was a 5.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 5.90% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.